146 related articles for article (PubMed ID: 15953282)
21. Demographic characteristics, presentations and treatment outcome of patients with prolactinoma.
Malik S; Hussain SZ; Basit R; Idress N; Habib A; Zamant M; Islam N
J Ayub Med Coll Abbottabad; 2014; 26(3):269-74. PubMed ID: 25671924
[TBL] [Abstract][Full Text] [Related]
22. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Cackett P; Eunson G; Bath L; Mulvihill A
Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
[TBL] [Abstract][Full Text] [Related]
23. Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.
Delgrange E; Donckier JE
J Clin Endocrinol Metab; 1999 Dec; 84(12):4746-7. PubMed ID: 10599747
[No Abstract] [Full Text] [Related]
24. Pons herniation into skull base after cabergoline therapy of giant prolactinoma.
Moles Herbera J; Rivero Celada D; Montejo Gañan I; Fustero de Miguel D; Fuentes Uliaque C; Vela Marín AC
Pituitary; 2015 Feb; 18(1):68-71. PubMed ID: 24522845
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
[No Abstract] [Full Text] [Related]
26. The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma.
Gürbüz F; Yağcı-Küpeli B; Kör Y; Yüksel B; Zorludemir S; Gürbüz BB; Küpeli S
J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):159-63. PubMed ID: 23945126
[TBL] [Abstract][Full Text] [Related]
27. Tumour shrinkage and chiasmal herniation after successful cabergoline treatment for a macroprolactinoma.
Marcos L; De Luis DA; Botella I; Hurtado A
Clin Endocrinol (Oxf); 2001 Jan; 54(1):126-7. PubMed ID: 11167937
[No Abstract] [Full Text] [Related]
28. Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
Yano S; Hide T; Uekawa K; Honda Y; Mikami Y; Kuratsu JI
World Neurosurg; 2016 Nov; 95():620.e17-620.e22. PubMed ID: 27535625
[TBL] [Abstract][Full Text] [Related]
29. A case of macroprolactinoma and elevated insulin-like growth factor-I in a young boy.
Eyal O; Naffaa LN; Elder DA
Acta Paediatr; 2005 Dec; 94(12):1852-4. PubMed ID: 16421054
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacologic cure of a pituitary macroprolactinoma].
Hurtado Amador R; Ayala AR
Ginecol Obstet Mex; 2003 Oct; 71():522-6. PubMed ID: 15002692
[TBL] [Abstract][Full Text] [Related]
31. Visual vignette. Cabergoline therapy.
Stanciu I; Gordon DL
Endocr Pract; 2003; 9(5):475. PubMed ID: 14583429
[No Abstract] [Full Text] [Related]
32. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Werner S
Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
[No Abstract] [Full Text] [Related]
33. [Serum concentrations of glucose, cholesterol and triglycerides in men with prolactinoma treated with cabergoline].
Iglesias P; Villabona C; Díez JJ
Med Clin (Barc); 2016 Nov; 147(10):466-467. PubMed ID: 27452305
[No Abstract] [Full Text] [Related]
34. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Lebbe M; Hubinont C; Bernard P; Maiter D
Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
[TBL] [Abstract][Full Text] [Related]
35. Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.
Verhelst JA
J Clin Endocrinol Metab; 1999 Dec; 84(12):4747. PubMed ID: 10599748
[No Abstract] [Full Text] [Related]
36. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
Delgrange E; Donckier J
J Clin Endocrinol Metab; 1997 Aug; 82(8):2755-6. PubMed ID: 9253367
[No Abstract] [Full Text] [Related]
37. Chronic cluster headache and the pituitary gland.
De Pue A; Lutin B; Paemeleire K
J Headache Pain; 2016; 17():23. PubMed ID: 26969187
[TBL] [Abstract][Full Text] [Related]
38. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
[TBL] [Abstract][Full Text] [Related]
39. Chronic cluster-like headache secondary to prolactinoma: uncommon cephalalgia in association with brain tumors.
Benitez-Rosario MA; McDarby G; Doyle R; Fabby C
J Pain Symptom Manage; 2009 Feb; 37(2):271-6. PubMed ID: 18694630
[TBL] [Abstract][Full Text] [Related]
40. [Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report].
Castro-Castro J; Torre-Eiriz JA; Pinzón-Millán A; Pastor-Zapata A
Neurocirugia (Astur); 2011 Dec; 22(6):558-61; discussion 561. PubMed ID: 22167286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
